Essential oils + 0.2% chlorhexidine + Sterile water

ApprovedCompleted
0 watching 0 views this week๐Ÿ”ฅ Hot
85
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Oral Biofilm

Conditions

Oral Biofilm, Mouthwash, Periodontitis

Trial Timeline

Sep 1, 2012 โ†’ โ€”

About Essential oils + 0.2% chlorhexidine + Sterile water

Essential oils + 0.2% chlorhexidine + Sterile water is a approved stage product being developed by Johnson & Johnson for Oral Biofilm. The current trial status is completed. This product is registered under clinical trial identifier NCT02124655. Target conditions include Oral Biofilm, Mouthwash, Periodontitis.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT02124655ApprovedCompleted

Competing Products

20 competing products in Oral Biofilm

See all competitors
ProductCompanyStageHype Score
AL001 + Placebo + Open label - AL001AlectorPhase 3
69
AL001AlectorPhase 2
44
AG013OragenicsPhase 2
44
LP-10 (Liposomal Tacrolimus)Lipella PharmaceuticalsPhase 2
44
Micafungin + FluconazoleAstellas PharmaPhase 3
77
micafungin + caspofunginAstellas PharmaPhase 3
77
Erlotinib + PlaceboAstellas PharmaPhase 3
77
AmifostineSun PharmaceuticalApproved
85
exenatide + Other antidiabetic therapiesEli LillyPre-clinical
23
Teriparatide 20 mcgEli LillyPhase 3
77
LY3884963 + Methylprednisolone + Optional Sirolimus + Optional PrednisoneEli LillyPhase 1/2
41
Baricitinib 4 milligram Oral TabletEli LillyPhase 2
52
tramadol hydrochloride + acetaminophenJohnson & JohnsonApproved
85
galantamine hydrobromideJohnson & JohnsonPhase 2
52
HR17031 injection + insulin glargineJiangsu Hengrui MedicinePhase 3
77
Camrelizumab + Camrelizumanb plus TPFJiangsu Hengrui MedicinePhase 2
52
Camrelizumab plus TP + TPJiangsu Hengrui MedicinePhase 3
77
AZD1981 + Neovletta 21/28 + Placebo AZD1981AstraZenecaPhase 1
33
DurvalumabAstraZenecaPhase 1/2
41
fostamatinib + Microgynonยฎ 30 (Oral contraceptive) + PlaceboAstraZenecaPhase 1
33